Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market

Patent expands intellectual property protection in one of the world's largest cartilage repair m

Patent expands intellectual property protection in one of the world's largest cartilage repair marke

The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling th

European Notified Body approves next-generation manufacturing process that increases production 5-fo

Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess

Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular se

HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Comp

Regentis Biomaterials Ltd. (RGNT) stock rises after withdrawing its Form F-1 registration statement

Shares of La-Z-Boy Inc (NYSE: LZB) rose 19.6% in pre-market trading after reporting better-than-expe

HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open

Regentis stock surged 506% Monday after withdrawing its planned public offering, before slipping in

US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech s

https://www.sec.gov/Archives/edgar/data/1912966/000121390026068601/ea0294796-6k_regentis.htm

US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks dow

GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT

GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair

Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after report

Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption R

Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe pla

$7.4 million in cash expected to provide runway to complete site expansion process and patient enrol

Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in

GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and

New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study,

2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture simila

Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cart

Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for s

The US IPO market entered the final stretch of the year with a few small listings, a wave of SPACs,

Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT)

Herzliya, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT)